ofatumumab,eculizumab,iptacopan,Ravulizumab
novartis,alexion pharmaceuticals
['dance', ' ofa ', 'eculizumab']
#ash22 de latour: primary endpoint hgb incr 2g/dl from baseline wo transfusion and hgb &gt;12g/dl. n=62 w iptacoban vs 35 with mab. hgb incr 2g/dl 82% with iptacoban vs 2% with mab. hgb &gt;12g/dl 68.8% vs 1.8%. transfusion avoidance 96% vs 26%. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)